Neuropore’s NPT520-34 Given FDA’s Orphan Drug Designation for ALS Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to NPT520-34, an investigational anti-neuroinflammatory molecule, for the…
Articles by Patricia Inácio, PhD
More Than Half of ALS Cases Have a Genetic Cause; Women Have Greatest Risk of Developing the Disease, Irish Study Suggests
More than 50% of the cases of amyotrophic lateral sclerosis (ALS) disease are linked with a genetic cause, and first-degree…
Targeting a Single Gene May Help Halt Production of Toxic Proteins in ALS, Study Suggests
New research has identified the RPS25 gene as a key player that allows the production of mutated C9orf72 protein —…
Gut Microbiome May Help Slow ALS Progression, Study Indicates
The gut microbiome — the natural collection of microorganisms living in our guts — might influence the progression of…
Enrollment Complete for ORARIALS-01 Trial of Arimoclomol in ALS Patients
Patient enrollment is now complete, ahead of schedule, for the Phase 3 ORARIALS-01 clinical trial assessing the effectiveness of Orphazyme’s…
Clinical Trial Testing H.P. Acthar Gel for ALS Terminated Due to Pneumonia Concerns
Mallinckrodt Pharmaceuticals has shut down its Phase 2b PENNANT clinical trial assessing the effectiveness and safety of H.P.
Scientists Recreate Human Peripheral Nerve Cells’ Interactions on a Chip
Researchers have created the first entirely human small chip that is able to replicate some of the cell-cell interactions occurring…
Small-Molecule Compounds ID’d That May Lessen Protein Buildup in Cells Under Stress, an ALS Hallmark
Researchers identified small-molecule compounds that help to prevent the build-up of stress-induced clumps of TDP-43 protein, a hallmark of amyotrophic…
Nanoparticles May Help Enhance Therapeutic Potential of Curcumin in Neurodegenerative Diseases, Review Suggests
Nanoparticles may help enhance the therapeutic potential of otherwise difficult-to-deliver agents, such as curcumin, in diseases affecting the central nervous…
Phase 2 Trial Testing H.P. Acthar Gel for ALS Enrolls Half of Patients, Still Recruiting
A Phase 2b clinical trial assessing the efficacy and safety of H.P. Acthar Gel, an experimental injectable therapy for…